[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368728-105":59,"doc-detail-368728-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","herv-derived-epitopes-represent-new-targets-for-t-cell-based-immunotherapies-in-ovarian-cancer-preclinical-rationale","HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer - Preclinical rationale","","Ovarian cancer remains highly lethal, and responses to checkpoint inhibitors are limited. Human endogenous retroviruses (HERVs) are aberrantly expressed in tumor cells and may provide shared T-cell epitopes for immunotherapy beyond reliance on tumor mutational burden. Using transcriptomic quantification, immunohistochemistry, immunopeptidomics, and functional T-cell assays, the study evaluates antigen presence, epitope presentation on HLA molecules, CD8+ T-cell recognition, and anti-tumor activity, including in vivo efficacy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/herv-derived-epitopes-represent-new-targets-for-t-cell-based-immunotherapies-in-ovarian-cancer-preclinical-rationale/368728/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/herv-derived-epitopes-represent-new-targets-for-t-cell-based-immunotherapies-in-ovarian-cancer-preclinical-rationale/368728.png","ImageObject",300,407,{"name":92,"@type":93},"Stanford","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are HERV-derived epitopes considered new targets for ovarian cancer immunotherapy?","Question",{"text":113,"@type":114},"HERVs are aberrantly expressed by ovarian tumor cells and can provide shared T-cell epitopes presented on HLA molecules, potentially enabling immune responses even when checkpoint inhibitor efficacy is poor.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were HERV expression and the presence of the HERV-K/HML-2 Gag antigen assessed?",{"text":118,"@type":114},"The work used transcriptomic analysis based on RNA sequencing for HERV-K sequences, and immunohistochemistry on ovarian cancer tumor microarrays and normal ovarian tissues to confirm antigen presence.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence supports that HERV-specific T cells can kill ovarian cancer cells?",{"text":122,"@type":114},"Immunopeptidomics showed epitope presentation on HLA molecules of ovarian tumor cell lines, and functional assays demonstrated that HERV-specific CD8+ T cells killed ovarian cancer cells in an HLA class I-restricted manner while sparing normal HLA-A2-positive primary cells.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368728,1790197785,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Open access Original research  \n HERV-derived epitopes represent new  \ntargets for T-cell-based  \nimmunotherapies in ovarian cancer  \nPaola Bonaventura,1,2 Audrey Page,1 Olivier Tabone,2 Yann Estornes,2  \nVirginie Mutez,2 Marie Delles,2 Sarah Moran,2 Clarisse Dubois,2 Thibault Richard,2 Marjorie Lacourrège,3 Marie Michelas,4 Dina M Tawfik,1 Ema Etchegaray,2 Adrian Valente,1 Rasha E Boulos,2 Gabriel Jimenez Dominguez,2 Isabelle Treilleux,5 Nicolas Chopin,5 Olivia Le Saux,1,5 Nicolas Chuvin,2 Nicolas Gadot,5  \nMaha Ayyoub  ,4,6 Qing Wang,7 Jenny Valladeau-Guilemond  ,1  \nStéphane Depil  1,2,5  \nTo cite: Bonaventura P, Page A, Tabone O, et al.  \nHERV-derived epitopes represent new targets for Tcell-based immunotherapies in ovarian cancer. Journal for ImmunoTherapy of Cancer 2025;13:e010099 . doi:10 . 1136/ jitc-2024-010099  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-010099](jitc-2024-010099)) .  \nAP and OT contributed equally. Accepted 15 July 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nProfessor Stéphane Depil; stephane.depil@lyon. unicancer. fr  \nABSTRACT  \nBackground Ovarian cancer represents the most lethal gynecological cancer with poor response to checkpoint inhibitors. Human endogenous retroviruses (HERVs) are aberrantly expressed by tumor cells and may represent a source of shared T-cell epitopes for cancer immunotherapy regardless of the tumor mutational burden.  \nMethods A transcriptomic analysis based on RNA sequencing was developed to quantify the expression of HERV-K sequences containing the selected epitopes. The presence of HERV-K/HML-2 Gag antigen was then assessed by immunohistochemistry (IHC) on tumor microarrays from ovarian cancer samples and normal ovarian tissues. A specific immunopeptidomics approach was developed to detect epitopes on human leukocyte antigens (HLA) molecules. Epitope-specific CD8+ T cells were quantified by multimer staining. HERV-specific T cells were obtained after in vitro stimulation of T cells from HLAA2-positive healthy donors or patients with ovarian cancer, and in vitro target cell killing was evaluated using realtime analysis. In vivo antitumor efficacy of HERV-specific T cells was assessed in an avian embryo model.  \nResults Epitope-containing HERV transcripts were significantly higher in ovarian cancers compared with normal tissues. The presence of the HERV-K/HML-2 Gag antigen was confirmed by IHC in 20/40 (50%) ovarian cancers while no Gag expression was found in normal ovarian tissue samples. Immunopeptidomics analysis revealed the presence of epitopes on HLA molecules on the surface of ovarian tumor cell lines but not on normal primary cells from critical tissues. Low percentages of HERV-specific T cells were detected among tumorinfiltrating lymphocytes from ovarian cancers. Furthermore, in vitro stimulation of patient T cells induced functional epitope-specific T cells, confirming the immunogenicity of these epitopes in patients with ovarian cancer. In vitro, HERV-specific T cells specifically killed ovarian cancer cells in an HLA class I-restricted manner while sparing normal HLA-A2-positive primary cells derived from critical tissues. Epitope-specific CD8+ T cells exhibited a strong antitumoral activity in vivo, inducing a highly significant decrease in tumor volume in comparison with control groups.  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Human endogenous retroviruses (HERV) expression has been described in different tumors including ovarian cancer.The characterization of HERV-derived tumor epitopes and of the corresponding T-cell responses remained to be performed to develop Tcell-based immunotherapies in ovarian cancer.\u003Cbr>WHAT THIS STUD","cbCaiikMjMZrJoWh","https://ap.wps.com/l/cbCaiikMjMZrJoWh","pdf",11245673,15,"English","# Abstract\n## Background\n## Methods\n## Results\n# Introduction\n## Clinical context and limits of checkpoint blockade\n## Rationale for tumor epitope targeting","[{\"question\":\"Why are HERV-derived epitopes considered new targets for ovarian cancer immunotherapy?\",\"answer\":\"HERVs are aberrantly expressed by ovarian tumor cells and can provide shared T-cell epitopes presented on HLA molecules, potentially enabling immune responses even when checkpoint inhibitor efficacy is poor.\"},{\"question\":\"How were HERV expression and the presence of the HERV-K/HML-2 Gag antigen assessed?\",\"answer\":\"The work used transcriptomic analysis based on RNA sequencing for HERV-K sequences, and immunohistochemistry on ovarian cancer tumor microarrays and normal ovarian tissues to confirm antigen presence.\"},{\"question\":\"What evidence supports that HERV-specific T cells can kill ovarian cancer cells?\",\"answer\":\"Immunopeptidomics showed epitope presentation on HLA molecules of ovarian tumor cell lines, and functional assays demonstrated that HERV-specific CD8+ T cells killed ovarian cancer cells in an HLA class I-restricted manner while sparing normal HLA-A2-positive primary cells.\"}]","HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer - Preclinical rationale | PDF",1790178233,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f14a1b4874480199332847ffb95c7c9.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5b45cba7bf556915bffd9a31877399d.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8009327ee3fcf4869c8508714002d6de.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7306fd17f118f16cf92439ceadab314c.webp",980,1306]